Core One Labs virtual town hall reveals the company is approaching
VANCOUVER, British Columbia, August 04, 2021 (GLOBE NEWSWIRE) – Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core A“) is a research and development company focused on bringing psychedelic drugs to market through the development and production of API grade psychedelic compounds, the advancement of assisted psychedelic treatments and the integration of a new delivery system technology The company is delighted to announce information regarding the status and timing of its revolutionary psilocybin technology which was presented by Dr. Robert EW Hancock, Executive Chairman, at its Virtual Town Hall Accessed Aug 4, 2021.
The patent is ready
“We already have a written patent, we could file it today, but we are suspending the filing of the patent until we have worked on all the possible modifications of the technology, a competitor could use to reproduce it…. There is tremendous value in maintaining this technology as an owner“Said Dr Hancock. “At this point, I estimate that we will be ready to file the patent in about a month and make more in-depth announcements on the technology in the following month.”
With a real opportunity for substantial profitability, Core One is doing everything to ensure that its technology is well protected.
“Currently, psilocybin is [very] Dear [when produced chemically or from mushrooms]…. We felt that we can produce it for much less“Said Dr Hancock. This takes into account inputs, equipment costs, labor and cleaning, and it positions Core One Labs to produce the the lowest cost psilocybin in the market.
Core One Labs’ proprietary production method will reshape the way the industry produces psilocybin. “The [general] method we use for the production and extraction of psilocybin is proven. The production method itself, which is a subsection of the production technology called ‘recombinant ‘ production technology, is used for very common substances such as the manufacture of insulin, human growth hormones or amino acids“Said Dr Hancock.
Core One has collaborated with one of the best institutions in the world to accelerate its research and further develop its technology. “The University of British Columbia is one of the top 30 universities in the world… Collaboration with UBC gives us access to all the great infrastructure of equipment and great minds.“Said Dr Hancock.
Dr Robert EW Hancock provided important updates on Core One operations and we encourage you to watch a recording of the Virtual Town Hall presentation on our website at www.core1labs.com. conclusion of the live event.
About Core One Labs Inc.
Core One is a biotechnology and life science technology research company focused on bringing psychedelic drugs to market through novel delivery systems and psychedelic-assisted psychotherapy. Core One has developed a patent pending thin film oral tape (the “Technology”) that instantly dissolves when placed in the mouth and delivers organic molecules in precise amounts into the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also owns a stake in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, the R&D related to psychedelic treatments and new drug therapies, the Company intends to obtain regulatory research approval for the advancement of treatments derived from psychedelics. for mental health disorders.
Core One Labs Inc.
Chief Executive Officer
FOR MORE INFORMATION PLEASE CONTACT:
The Canadian Securities Exchange has not reviewed and accepts no responsibility for the adequacy or accuracy of the contents of this press release.
The information contained in this press release contains forward-looking statements based on assumptions as of the date of this press release. These statements reflect the current estimates, beliefs, intentions and expectations of management. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of important factors, many of which are beyond the control of the Company. These factors include, among others: risks and uncertainties associated with the Company’s limited operating history and the need to comply with strict regulatory regulations. Therefore, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Unless required by applicable securities legislation, the Company assumes no obligation to publicly update or revise forward-looking information.
In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offense to possess substances under the Controlled Drugs and Substances Act (Canada) without prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One has no direct or indirect involvement in the illegal sale, production or distribution of psychedelics in the jurisdictions in which it operates. While Core One believes that psychedelics can be used to treat certain medical conditions, it does not advocate legalizing psychedelics for recreational purposes. Core One does not deal with psychedelics except in laboratory and clinical trials conducted under approved regulatory frameworks.